Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dalfampridine
Drug ID BADD_D00574
Description Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Indications and Usage Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
Marketing Status approved
ATC Code N07XX07
DrugBank ID DB06637
KEGG ID D04127
MeSH ID D015761
PubChem ID 1727
TTD Drug ID D08YIN
NDC Product Code 10144-427; 63190-0510; 67877-444; 56125-427; 0591-2533; 65862-917; 62756-429; 63629-9450; 65862-863; 38779-3205; 42571-338; 51927-5030; 42571-275; 0378-4504; 12817-054; 46016-5042; 54382-125; 62756-038; 62991-3143; 65372-1157; 16729-292; 63190-0530; 51407-246; 0054-0479
UNII BH3B64OKL9
Synonyms 4-Aminopyridine | 4 Aminopyridine | Dalfampridine | Pymadine | VMI-103 | VMI 103 | VMI103 | 4-Aminopyridine Sustained Release | 4 Aminopyridine Sustained Release | Sustained Release, 4-Aminopyridine | Fampridine-SR | Fampridine SR
Chemical Information
Molecular Formula C5H6N2
CAS Registry Number 504-24-5
SMILES C1=CN=CC=C1N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gallbladder disorder09.03.02.0010.001077%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Generalised tonic-clonic seizure17.12.01.0020.003230%Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.0060.005383%
Headache17.14.01.0010.110415%
Hemiparesis17.01.04.0010.003015%
Hemiplegia17.01.04.0020.000538%Not Available
Hunger14.03.02.012; 08.01.09.0030.000538%Not Available
Hyperreflexia17.02.01.0020.001184%Not Available
Hypersensitivity10.01.03.0030.022772%
Hypersomnia19.02.05.001; 17.15.01.0010.005114%
Hyperventilation22.02.01.006; 19.01.02.0040.000538%Not Available
Hypoaesthesia17.02.06.023; 23.03.03.0810.029878%Not Available
Hypokinesia17.01.02.0090.007214%Not Available
Hypotension24.06.03.002--
Immune system disorder10.02.01.0010.001184%Not Available
Incontinence07.01.06.011; 20.02.02.004; 17.05.01.0060.005922%Not Available
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.0100.005383%
Ingrowing nail23.02.05.0110.001830%Not Available
Initial insomnia17.15.03.005; 19.02.01.0050.002100%Not Available
Injection site bruising24.07.06.017; 23.03.11.015; 12.07.03.042; 08.02.03.0420.001830%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.002746%Not Available
Injection site haematoma24.07.01.009; 12.07.03.004; 08.02.03.0040.001184%Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.0050.000538%Not Available
Injection site induration12.07.03.007; 08.02.03.0070.001184%Not Available
Injection site mass08.02.03.009; 12.07.03.0100.003930%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.005653%Not Available
Injection site reaction12.07.03.015; 08.02.03.0140.001184%
Injection site vesicles23.03.01.024; 12.07.03.051; 08.02.03.0510.001830%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages